Seizure prophylaxis in hypertensive pregnancies: a framework for making clinical decisions
- 1 October 1997
- journal article
- review article
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 104 (10) , 1173-1179
- https://doi.org/10.1111/j.1471-0528.1997.tb10942.x
Abstract
Objective To describe a framework for generating therapeutic recommendations using seizure prophylaxis in hypertensive pregnancies as an example.Design A decision‐making framework was built using: 1. evidence of therapeutic benefit, with number needed to treat as the effect measure; 2. baseline rates of the target disorder that the treatment was designed to prevent; and 3. a treatment threshold, determined by weighting the potential risks against the potential benefits of the treatment.Methods Evidence of therapeutic benefit (i.e. reduction in eclamptic seizures associated with magnesium sulphate therapy in hypertensive pregnancies) was determined by a systematic quantitative overview of controlled clinical trials. Baseline rates of seizures without magnesium sulphate therapy were derived from a recent cohort study. A treatment threshold was generated using estimates of treatment associated morbidities which were weighted against the potential reduction in seizures from magnesium sulphate therapy considering the relative values assigned to these outcomes by obstetricians practising in our hospital.Results The number of hypertensive women needed to be treated with magnesium sulphate to prevent a single case of eclamptic seizures varied in a curvilinear fashion dropping from 1000 to 14 as the baseline rate of seizures increased from 0.1% to 10%. The treatment threshold as measured by number needed to treat was 64 (range 57–77). The number needed to treat for nonproteinuric hypertension was 1000 (95% CI 180–40,000), whereas it was 32 (95% CI 20–57) for proteinuric hypertension. Considering the uncertainty in estimation of the numbers needed to treat and treatment threshold, magnesium sulphate therapy may be recommended for women at high risk of eclampsia (e.g. severe pre‐eclampsia) while it should be withheld in cases at low risk (e.g. nonproteinuric hypertension and mild pre‐eclampsia).Conclusion While awaiting further research obstetricians intuitively make decisions about seizure prophylaxis in hypertensive pregnancies. Our decision‐making framework generated therapeutic recommendations by explicit consideration of the available evidence.Keywords
This publication has 23 references indexed in Scilit:
- Authors' replyBJOG: An International Journal of Obstetrics and Gynaecology, 1997
- Magnesium sulphate in the treatment of eclampsia and pre‐eclampsia: an overview of the evidence from randomised trialsBJOG: An International Journal of Obstetrics and Gynaecology, 1996
- Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working GroupJAMA, 1995
- Does magnesium sulfate affect the length of labor induction in women with pregnancy-associated hypertension?American Journal of Obstetrics and Gynecology, 1995
- Users' guides to the medical literature. VII. How to use a clinical decision analysis. B. What are the results and will they help me in caring for my patients? Evidence Based Medicine Working GroupJAMA, 1995
- Clinically useful measures of effect in binary analyses of randomized trialsJournal of Clinical Epidemiology, 1994
- Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working GroupJAMA, 1994
- Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working GroupJAMA, 1994
- Management of severe pre-eclampsia and eclampsia by UK consultantsBJOG: An International Journal of Obstetrics and Gynaecology, 1992
- An Assessment of Clinically Useful Measures of the Consequences of TreatmentNew England Journal of Medicine, 1988